Evidence map›Paper›PMID 40706050›Full record

ArticleBlood advances2025

The IL7 receptor and the RAG complex are required for the onset of B-cell acute lymphoblastic leukemia.

Audrey Dauba, Emmanuelle Näser, Antoine Nouhaud, Eric Delabesse, Bastien Gerby, Ahmed Amine Khamlichi

Abstract read
In one paragraph

Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Audrey DaubaInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, Centre National de la Recherche Scientifique, Toulouse, France.
Emmanuelle NäserInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, Centre National de la Recherche Scientifique, Toulouse, France.
Antoine NouhaudCHU Toulouse, INSERM, Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Centre National de la Recherche Scientifique, Toulouse, France.ORCID 0009-0002-9018-6613
Eric DelabesseCHU Toulouse, INSERM, Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Centre National de la Recherche Scientifique, Toulouse, France.ORCID 0000-0002-0928-0753
Bastien GerbyCHU Toulouse, INSERM, Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Centre National de la Recherche Scientifique, Toulouse, France.ORCID 0000-0002-2657-4200
Ahmed Amine KhamlichiInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, Centre National de la Recherche Scientifique, Toulouse, France.ORCID 0000-0002-6523-2035

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40706050
PMCPMC12516033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.